drugset / Trial / NCT03465540
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.
Timeline
- Start
- 2018-08-17
- Primary completion
- 2019-07-25
- Completion
- 2019-07-25
Outcome
Outcome not reported
Stopped (Business): “Strategic decisions”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Intravenous |
| Subject | Dexamethasone | Small molecule | — | Intravenous |
| Subject | MURIZATOCLAX | Small molecule | — | Oral |